Member Info for B2HS2L

1 A full reveal of the 40 day blackout ruling nobody seems to know about, (nor anyone on other boards).

2 A promise that we see no more Paul Hill interviews.

Rory,

A time I think for explaining some of the business / finance issues surrounding AS leadership in 2024.

AS leaves a legacy that requires explanation.

CC has the platform to paint a broader picture of how the situation can be improved.

CLN reduction a priority for CC (I hope)

Comms improvement

CFO's addition / subtraction error via RNS must be high on CC's 'must rectify' list, and it won't be arithmetic lessons for the CFO

We won't hear it today, but CC must be very dissatisfied about the exchange Avacta trades on.

Looking for that to change as a priority.

And your 17 next birthday

And you've been interested in this stock for 10 minutes, - 15 at most..

Kat

This RNS announces a new leader, not who what where when and how the new leader will lead.

This is what the market will be waiting for, and the sp will reflect that.

Agree Notrex. _ board replacements possibly from USA.

I'm thinking CC has lined up / is lining up replacement board members.

Like new R&D head.

Like new comms team

Why not now the focus is Therapeutics in USA.

Thanks Wilson.

I found these Exmex - perhaps you might have seen something different.

https://caseboard.io/cases/?prod_caseboard_cases%5Bquery%5D=yourgene

Still unsure shares have yet found sticky fingers, - we will know if sp plateaus at 51-54 p.

Caveat here is if good news arrives on Tuesday, - seeing any plateau blown away.

2 Jan 2024 - RNS -

Steve Gibson - Appointment of CFO

Commenting, James Wakefield, Non-Executive Chairman, said: "We are delighted to welcome Steve as our CFO. He has impressed us with his financial and operational expertise and was instrumental in the acquisition of Yourgene Health plc as well as delivering the strategic changes to the Company over the last two years. The Board looks forward to working with him as we continue to execute our growth strategy."

IMO that's JW saying SG is his financial man, and LR will have to budget his plans accordingly, else SG will advise JW of overspend.

Cut him some slack, it's difficult using your calculator single handed when you're busy trying to reduce your prostate cancer risk with the other hand.

Apologies PL, couldn't resist.

Are all the Abacus beads in place?

5,277,257 + 6,500,000 - 2,058,000 = 11,777,257

¯\_(ツ)_/¯

Https://hallellis.co.uk/summary-judgment-applications-defences/ - Thanks Neil.

'What is Summary Judgment?

Summary judgment is a court order - judgment - which brings litigation to an end early.

The legal proceedings are brought to an end when, at a hearing of a summary judgment application a court finds that the CLAIM or the DEFENCE:

has no real prospect of success, and

there is no other compelling reason why the case should be allowed to proceed to trial.

Courts say that summary judgment is:

designed to deal with cases that are not fit for trial at all: Lord Woolf in Swain v Hillman (1999), the Court of Appeal

The judgment avoids a close examination of all the evidence which might be produced at the usual end point of litigation, which is the trial.

The parties are saved significant time, expense, worry and the distraction of enduring the entire litigation process through to the trial. There is no point.'

+++

The court will also hear an application by the DHSC for summary judgment in relation to one aspect of its claim, as part of which the DHSC is seeking judgment.

If that one aspect is set aside by the court, what else is left in the DHSC armoury?

I'm wondering if it has ever occurred that the court decides the claimant's Summary Judgment application

is the case that has no real prospect of success, in which case settlement is early May.

How likely might that be?

Sheppy in Premier league, me non-league.

I keep in mind that news might increase sp at any time, so plough on.

As you say Alcibiades,

Bachovin, Tufts Medical School, and Avacta own the patents behind PRECISION.

All three need to be satisfied by any company assuming ownership of Avacta's patent rights on purchase of Avacta.

09.04.2024 - Christina Coughlin delivered this quote in an RNS, hitting the nail on the head.

"The proof-of-concept data presented today with AVA6000 suggest that the peptide drug conjugate drug class has several key advantages, particularly the tumor-specificity of the release of doxorubicin through targeting FAP and simplicity of the manufacturing process which results in significant savings in the cost of goods."

She is discussing a market disrupting platform, and BP have been waiting for the trial to mature before showing interest.

IMO the point in time when Avacta receives FDA Approval will possibly be the catalyst for a Takeover

Currently buying the dips, how long this opportunity lasts is unknown.

Moderators have deleted this this morning, wouldn't you say so Oz?

Worth repeating I'd say

Eliot Forster

“And the really cool thing about our technology and there is not many companies on the planet who have this and lots are saying we want it, is that we hit the barricade and the actual cancer cells themselves, both at the same time and that’s a very cool thing.”

BoD detailing a Long Term Incentive Plan.

Not thinking about how to repay £ millions back to DHSC after losing a court case.

Every picture tells a story.